Discontinued — last reported Q1 '18
Regeneron Pharmaceuticals Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments increased by 71.1% to $571.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 80.4%, from $316.80M to $571.60M. Over 5 years (FY 2020 to FY 2025), Equity Securities Without Readily Determinable Fair Value - Cumulative Downward Adjustments shows an upward trend with a 41.3% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase indicates deteriorating performance or valuation write-downs in the private equity or venture portfolio.
The cumulative amount of downward fair value adjustments recognized for equity securities that lack a readily determinab...
Standard for firms with significant private equity or venture capital exposure.
equity_securities_no_fv_downward_adj| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $40.00M | $40.00M | $40.00M | $46.70M | $47.30M | $48.30M | $48.30M | $48.30M | $78.30M | $60.80M | $74.30M | $73.70M | $196.80M | $159.80M | $159.80M | $316.80M | $316.80M | $316.80M | $334.00M | $571.60M |
| QoQ Change | — | +0.0% | +0.0% | +16.8% | +1.3% | +2.1% | +0.0% | +0.0% | +62.1% | -22.3% | +22.2% | -0.8% | +167.0% | -18.8% | +0.0% | +98.2% | +0.0% | +0.0% | +5.4% | +71.1% |
| YoY Change | — | — | — | — | +18.3% | +20.8% | +20.8% | +3.4% | +65.5% | +25.9% | +53.8% | +52.6% | +151.3% | +162.8% | +115.1% | +329.9% | +61.0% | +98.2% | +109.0% | +80.4% |